Dr. Raman Tuli

Participe à 2 sessions

Sessions auxquelles Dr. Raman Tuli participe

Samedi 26 Juin, 2021

Fuseau horaire: (GMT-05:00) Eastern Time (US & Canada)
3:50 PM
Faricimab in Neovascular Age-Related Macular Degeneration: One-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials
3:51 PM - 3:59 PM | 8 minutes
Rétine

Authors: Raman Tuli, 1.Carlos Quezada Ruiz, 2.David Silverman, 3.Vaibhavi Patel, 4.Karen Basu, 5.Hugh Lin. Author Disclosure Block: R. Tuli: Any direct financial payments including receipt of honoraria; Name of for-profit or not-for-profit organization(s); Hoffman Laroche Ltd. Any direct financial payments including receipt of honoraria; Description of relationship(s); Consultant. Funded grants or clinical trials; Name of for-profit or no...

Dimanche 27 Juin, 2021

Fuseau horaire: (GMT-05:00) Eastern Time (US & Canada)
4:05 PM
Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab(PDS) for Patients With Neovascular AMD
4:07 PM - 4:15 PM | 8 minutes
Rétine

Authors: Raman Tuli, Peter A. Campochiaro, Natasha Singh, David Kardatzke, Steven Blotner, Shienal Patel, Giulio Barteselli. Disclosure Block: R. Tuli: Any direct financial payments including receipt of honoraria; Name of for-profit or not-for-profit organization(s); Hoffmann La Roche. Any direct financial payments including receipt of honoraria; Description of relationship(s); Consultant. Funded grants or clinical trials; Name of for-profit or...